Tuesday, November 17, 2026

Revamping the Culture of Legacy Companies. The "Challenge" of Overcoming a Period of Industry Transformation.

Taisho Pharmaceutical, well-known for its "eagle" logo, has launched an accelerator program. With a business and brand that boasts the top market share in Japan and abroad, what issues motivated Taisho Pharmaceutical to launch the accelerator program? We interviewed Mr. Ken Uehara, Representative Director and Executive Vice President, to find out what kind of value they are trying to create through co-creation with startups.

Deregulation and drug price issues have brought the pharmaceutical industry into a period of change.

--What kind of transition did Taisho Pharmaceutical go through before introducing the Accelerator Program?

Founded in 1912, Taisho Pharmaceutical has developed and marketed ethical pharmaceuticals in the "Ethical Pharmaceuticals Business" and "Self-Medication Business" in Japan and overseas, developing and marketing medicines and health foods that can be purchased at pharmacies. Among these, Taisho boasts the largest market share in Japan for OTC drugs, which can be purchased at pharmacies and drugstores without a prescription.

The steadily growing industry began to change in the mid-1990s and early 2000s, when price competition began in the OTC drug market.

Until then, OTC drug prices had been set by manufacturers based on the resale system, or fixed prices, but around 1995, the resale system for energy drinks was abolished. Since then, the resale system has been abolished for other OTC drugs as well, allowing drugstores and other retailers to set prices freely, and price competition has begun.

over-the-counter drug

Around the same time, nutritional drinks went from being pharmaceutical products purchased only at pharmacies to a new category of quasi-drugs that could also be purchased at convenience stores. This expanded the market quickly, but the inability to set retail prices caused unit prices to fall and sales to stagnate over the long term.

Against this backdrop, Taisho Pharmaceutical started its overseas business in earnest in the late 2000s in order to find its next avenue for growth overseas. Although Taisho had been selling its own products overseas, it created a new pillar of business by acquiring companies handling OTC drugs in Indonesia, Malaysia, Mexico, Vietnam, France, and other countries.

--Have there been any changes in the area of prescription drugs?

The structure surrounding "drug prices" for ethical drugs is undergoing a review in order to curb the increase in social security costs associated with the increase in longevity. In addition, the government is strongly promoting the use of "generics," which are less expensive than brand-name drugs, in order to reduce medical costs, creating a difficult environment for manufacturers developing new drugs as a whole.

ethical pharmaceuticals

Until now, drug prices did not fall rapidly, so stable profits were allocated to the development of new drugs. But now, when a generic drug is released, the amount of prescriptions drops all at once, and drug prices drop more rapidly than before, so the time margin given to develop the next new drug has become extremely short.

So it became necessary to review the business model not only for Taisho Pharmaceutical but for the industry as a whole.

What was missing was the behavioral habit and culture of trying new things.

--What has been done to change the business model?

There are several brands that are the main competitors, but no matter how hard you try, it is difficult to increase sales in the same sales channel. One day, there will not be an increase in the number of people buying Lipovitan D in large quantities at a certain local drugstore.

So we thought we had two choices: find a new sales channel for our existing brand, or create a new brand and leverage our existing sales channel. Of course, there are new businesses that develop new products with new sales channels, but first we decided to create new demand and sales by utilizing our own business assets.

We have therefore begun entering categories we had not previously entered and developing renewal products that make the most of our existing brands. Examples include the energy drink RAIZIN, the diet drink Kobala Support, and mail-order health foods and skincare products.

However, what came to light in the process of launching these new businesses was the issue that new businesses cannot be created without a top-down approach. We cannot continue in the same top-down manner for the foreseeable future, but voices were not raised from the bottom-up.

That is no wonder, since the employees who are currently active in the company have only experienced "promoting" existing businesses that are already well known.

Employees who have worked diligently, having been taught that work is about "improving operational efficiency" rather than creating some new value, do not have the behavioral habits and culture in place to take on new challenges.

So, of course, we are not in the habit of diving into new sales channels or networking with people outside the company to create new business.

Since it is difficult to change these employees' work styles and attitudes toward work overnight, we felt that we needed to create an environment where they are continuously exposed to new information and stimulated.

Transforming the culture of legacy companies with the enthusiasm and challenging spirit of a startup

--So that sense of challenge led you to this accelerator program?

That is correct. Even if we are not able to commercialize the project as a result, it will be very valuable to the company if our employees can learn about a world they did not know, foster a desire to challenge themselves, and encounter interesting things they want to do by networking with people from startups.

The raison d'être of a manufacturer is to make people feel the value of the products they produce, buy them, and like them. However, as the size of the company grows, it becomes commonplace for things to sell, and people lose interest in them.

But if we put ourselves in an environment where we can constantly receive feedback from society, we will understand the views of people outside the company on issues and the cutting-edge services available in the world, and we will start to think about how our business is valued by the public and how we can make it better. This will then give us the opportunity to shape what we should do and the future we should aim for.

So we are not necessarily looking for short-term returns in this accelerator program. Of course, we would be happy if we could commercialize the project, but we are hoping that employees will learn about social issues, ways of working, and speed that they would not know if they were closed inside, which will lead to a change in culture, from which they will be able to identify social issues that need to be solved.

Hiring people at the same cost as the accelerator program will not change anything.

--Since open innovation is co-creation with the outside world, there are collaborations with large companies and government agencies. Among these, why did you choose startups, which is Creww's specialty?

I believe that the advantages of working with a large company or established organization are quite different from the advantages of a startup. With large companies, we co-create with minimal risk while leveraging each other's assets, but if things don't work out, we will often stop there.

On the other hand, startups and growth-oriented companies change hands to achieve their goals and continue to take on challenges in order to succeed. Even if it is risky, they will take action first, and if they fail, they will make the most of it and keep on running.

This spirit of challenge is something Taisho Pharmaceutical lacks, which is why I wanted employees to be exposed to the enthusiasm and seriousness of the startup.

--What was the reaction of other board members when you started the accelerator program?

I told them my thoughts and ideas, and they shared them. He said that even if no business comes out of it, we can have a relationship with startups, and if we can understand services and advanced technologies that we don't know about, let's give it a try.

There was also the issue of cost, but even if we used the cost of the accelerator program to cover personnel costs and hired three or four people, we would never get the same value as working with a startup.

What kind of chemical reactions will emerge from a network of people who are our opposites? It could be the seed of an idea, a new business, or a culture change. In any case, nothing will come of it as it is now, so I can't help but look forward to this initiative. And one more thing. As a byproduct of working on the accelerator program, I would be happy if people get the message that Taisho is a company that is open and listens to what people outside the company have to say from the ground up, and if we can create a future where more people and companies think, "Let's give it a try and sell it.

interviewer
Ken Uehara Executive Vice President and Representative Director, Taisho Pharmaceutical Co.
Born in Tokyo, 1977
B.A. in Economics, Keio University, 2000
B.A. (MBA), Tuck School of Business, 2006
2004 Joined Taisho Pharmaceutical Co.
2011 Managing Director, Taisho Pharmaceutical Holdings Co.
2012 Senior Managing Director, Taisho Pharmaceutical Co.
2013 Director, Taisho Pharmaceutical Holdings Co.
2014 Vice President and Representative Director, Taisho Pharmaceutical Co.
2017 Chairman of the Board, Biofermin Pharmaceuticals, Inc.
Tomomi Tamura
He joined Snow Brand Milk Industry in 2000. He then worked for an advertising agency and as a sole proprietor before joining BizReach in 2012. Engaged in content creation, he joined NewsPicks in 2016 as an editor on the BrandDesign team, and is now a freelance writer and editor.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。